Comparison of Bone Marrow-vs. Adipose Tissue-derived Mesenchymal Stem Cells for Attenuating Liver Fibrosis

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2017 Dec 30

PMID 29285145

Citations 26

Authors

Tianpao Hao

Jingfeng Chen

Shaoce Zhi

Qiyu Zhang

Gang Chen

Fuxiang Yu

Affiliations

Soon will be listed here.

Abstract

Mesenchymal stem cell (MSC) therapy has emerged as a potential novel method of treating liver fibrosis. To date, bone marrow-derived MSCs (BM-MSCs) and adipose tissue-derived MSCs (AD-MSCs) have not been analyzed with respect to their ability to combat liver fibrosis. The present study aimed to compare the capabilities of BM-MSCs and AD-MSCs in the treatment of liver fibrosis. BM-MSCs and AD-MSCs were taken from male Sprague-Dawley rats and cultured. Hepatic stellate cells (HSCs) were co-cultured with either BM-MSCs or AD-MSCs, and the effects of BM-MSCs or AD-MSCs on the proliferation, activation and apoptosis of HSCs were determined. The secretion of a selected group of cytokines by BM-MSCs and AD-MSCs was measured using enzyme-linked immunosorbent assays. Using a CCl-induced liver fibrosis animal model, the anti-inflammatory and anti-fibrotic effects of BM-MSCs or AD-MSCs against liver fibrosis were evaluated. The morphological examination and analysis of specific surface markers confirmed the successful preparation of BM-MSCs and AD-MSCs. Furthermore, the proliferation, activation and apoptosis of HSCs were significantly inhibited by BM-MSCs and AD-MSCs, with statistically greater reductions achieved by AD-MSCs compared with BM-MSCs. Direct comparison of the secretion of selected cytokines by BM-MSCs and AD-MSCs revealed that significantly higher levels of nerve growth factor and transforming growth factor-β1 were secreted in the AD-MSC culture medium, whereas levels of vascular endothelial growth factor and interleukin-10 did not differ significantly between AD-MSCs and BM-MSCs. studies using a CCl-induced liver fibrosis model demonstrated that inflammatory activity and fibrosis staging scores were significantly lower in the MSC-treated groups compared with controls. Although AD-MSCs improved anti-inflammatory and anti-fibrotic effects compared with BM-MSCs, these differences were not significant. Thus, the current study demonstrated that BM-MSCs and AD-MSCs are similarly effective at attenuating liver fibrosis by inhibiting the activation and proliferation of HSCs, as well as promoting the apoptosis of HSCs.

Citing Articles

Effectiveness and mechanisms of mesenchymal stem cell therapy in preclinical animal models of hepatic fibrosis: a systematic review and meta-analysis.

Wang X, Wang Y, Lu W, Qu J, Zhang Y, Ye J Front Bioeng Biotechnol. 2024; 12:1424253.

PMID: 39104627 PMC: 11299041. DOI: 10.3389/fbioe.2024.1424253.

Stem cell-based therapy for fibrotic diseases: mechanisms and pathways.

Taherian M, Bayati P, Mojtabavi N Stem Cell Res Ther. 2024; 15(1):170.

PMID: 38886859 PMC: 11184790. DOI: 10.1186/s13287-024-03782-5.

Comparison between the Regenerative and Therapeutic Impacts of Bone Marrow Mesenchymal Stem Cells and Adipose Mesenchymal Stem Cells Pre-Treated with Melatonin on Liver Fibrosis.

Elzainy A, El Sadik A, Altowayan W Biomolecules. 2024; 14(3).

PMID: 38540717 PMC: 10968153. DOI: 10.3390/biom14030297.

Synergistic Hepatoprotective Effects of Mesenchymal Stem Cells and Platelet-Rich Plasma in a Rat Model of Bile Duct Ligation-Induced Liver Cirrhosis.

Shivaramu S, Maiti S, Banu S, Kalaiselvan E, Sharun K, Mishra M Cells. 2024; 13(5.

PMID: 38474368 PMC: 10931218. DOI: 10.3390/cells13050404.

Intrapancreatic autologous stem cell therapy for type 1 diabetes - an experimental study.

Jawale S Ann Med Surg (Lond). 2023; 85(9):4355-4371.

PMID: 37663700 PMC: 10473305. DOI: 10.1097/MS9.0000000000000837.

References

Chen Y, Huang Y, Zheng W, Chen Z, Zhang L, Wang X . Interleukin-10 gene modification attenuates hepatocyte activation of rat hepatic stellate cells in vitro. Mol Med Rep. 2012; 7(2):371-8. DOI: 10.3892/mmr.2012.1228. View

Sato Y, Araki H, Kato J, Nakamura K, Kawano Y, Kobune M . Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. Blood. 2005; 106(2):756-63. DOI: 10.1182/blood-2005-02-0572. View

Lu T, Yang C, Sun H, Lv J, Zhang F, Dong X . FGF4 and HGF promote differentiation of mouse bone marrow mesenchymal stem cells into hepatocytes via the MAPK pathway. Genet Mol Res. 2014; 13(1):415-24. DOI: 10.4238/2014.January.21.9. View

Dezawa M, Ishikawa H, Itokazu Y, Yoshihara T, Hoshino M, Takeda S . Bone marrow stromal cells generate muscle cells and repair muscle degeneration. Science. 2005; 309(5732):314-7. DOI: 10.1126/science.1110364. View

Yu J, Zhang S, Chu E, Go M, Lau R, Zhao J . Peroxisome proliferator-activated receptors gamma reverses hepatic nutritional fibrosis in mice and suppresses activation of hepatic stellate cells in vitro. Int J Biochem Cell Biol. 2010; 42(6):948-57. DOI: 10.1016/j.biocel.2010.02.006. View

Iyer S, Cheng G . Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol. 2012; 32(1):23-63. PMC: 3410706. DOI: 10.1615/critrevimmunol.v32.i1.30. View

Majumder S, Piguet A, Dufour J, Chatterjee S . Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis. Eur J Pharmacol. 2013; 705(1-3):86-95. DOI: 10.1016/j.ejphar.2013.02.026. View

Ma Z, Lv X, Zhan L, Chen L, Zou Q, Xiang J . Human urokinase-type plasminogen activator gene-modified bone marrow-derived mesenchymal stem cells attenuate liver fibrosis in rats by down-regulating the Wnt signaling pathway. World J Gastroenterol. 2016; 22(6):2092-103. PMC: 4726681. DOI: 10.3748/wjg.v22.i6.2092. View

Qi Z, Zhang Y, Liu L, Guo X, Qin J, Cui G . Mesenchymal stem cells derived from different origins have unique sensitivities to different chemotherapeutic agents. Cell Biol Int. 2012; 36(9):857-62. DOI: 10.1042/CBI20110637. View

10.

Bosch J, Garcia-Pagan J . Complications of cirrhosis. I. Portal hypertension. J Hepatol. 2000; 32(1 Suppl):141-56. DOI: 10.1016/s0168-8278(00)80422-5. View

11.

Bataller R, Brenner D . Liver fibrosis. J Clin Invest. 2005; 115(2):209-18. PMC: 546435. DOI: 10.1172/JCI24282. View

12.

Salem H, Thiemermann C . Mesenchymal stromal cells: current understanding and clinical status. Stem Cells. 2009; 28(3):585-96. PMC: 2962904. DOI: 10.1002/stem.269. View

13.

Yu F, Su L, Ji S, Zhang S, Yu P, Zheng Y . Inhibition of hepatic stellate cell activation and liver fibrosis by fat-specific protein 27. Mol Cell Biochem. 2012; 369(1-2):35-43. DOI: 10.1007/s11010-012-1366-z. View

14.

Das M, Sundell I, Koka P . Adult mesenchymal stem cells and their potency in the cell-based therapy. J Stem Cells. 2014; 8(1):1-16. View

15.

Liu Y, Wang Z, Wang J, Lam W, Kwong S, Li F . A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-β and vascular endothelial growth factor signalling. Liver Int. 2013; 33(4):504-15. DOI: 10.1111/liv.12034. View

16.

Berardis S, Lombard C, Evraerts J, El Taghdouini A, Rosseels V, Sancho-Bru P . Gene expression profiling and secretome analysis differentiate adult-derived human liver stem/progenitor cells and human hepatic stellate cells. PLoS One. 2014; 9(1):e86137. PMC: 3906387. DOI: 10.1371/journal.pone.0086137. View

17.

Chamberlain G, Fox J, Ashton B, Middleton J . Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007; 25(11):2739-49. DOI: 10.1634/stemcells.2007-0197. View

18.

Yu F, Ji S, Su L, Wan L, Zhang S, Dai C . Adipose-derived mesenchymal stem cells inhibit activation of hepatic stellate cells in vitro and ameliorate rat liver fibrosis in vivo. J Formos Med Assoc. 2015; 114(2):130-8. DOI: 10.1016/j.jfma.2012.12.002. View

19.

Sharma R, Pollock K, Hubel A, McKenna D . Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. Transfusion. 2014; 54(5):1418-37. PMC: 6364749. DOI: 10.1111/trf.12421. View

20.

Liedtke C, Luedde T, Sauerbruch T, Scholten D, Streetz K, Tacke F . Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. Fibrogenesis Tissue Repair. 2013; 6(1):19. PMC: 3850878. DOI: 10.1186/1755-1536-6-19. View